Neuroendocrine and emotional regulation pathways (HPA axis)

The neuroendocrine and emotional regulation pathways, primarily centered on the hypothalamic-pituitary-adrenal (HPA) axis, constitute a critical system for maintaining physiological homeostasis and managing the body's response to stress (StatPearls, 2023 [https://www.ncbi.nlm.nih.gov/books/NBK541123/]). This complex network involves the sequential release of corticotropin-releasing hormone (CRH) from the hypothalamus, adrenocorticotropic hormone (ACTH) from the pituitary, and glucocorticoids like cortisol from the adrenal glands (NIH, 2022 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181830/]). These hormones interact with specific receptors throughout the brain and body to regulate mood, energy metabolism, and immune function. Dysregulation of these pathways, often characterized by impaired negative feedback, is a key factor in the pathophysiology of psychiatric conditions such as major depression, anxiety, and PTSD (Nature Reviews Neuroscience, 2005 [https://www.nature.com/articles/nrn1646]). While the pathway itself is not a single molecular target, its individual components—such as the glucocorticoid receptor (GR) and CRH receptors—are major focuses for drug development (Journal of Clinical Investigation, 2013 [https://www.jci.org/articles/view/63005]). Pharmacological interventions aim to restore balance within these pathways to alleviate symptoms of both endocrine and mental health disorders (PubMed, 2014 [https://pubmed.ncbi.nlm.nih.gov/25035247/]).

Other names

Hypothalamic-pituitary-adrenal axisStress response systemNeuroendocrine-immune axisLimbic-hypothalamic-pituitary-adrenal axis

Modulation of the hypothalamic-pituitary-adrenal (HPA) axis through receptor agonism or antagonism (e.g., glucocorticoid receptors) and inhibition of steroidogenesis to normalize hormonal feedback loops and emotional processing.